- Home
- DLHC vs PRLD Comparison
DLHC vs PRLD Comparison
Compare DLHC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLHC | PRLD |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 207.5M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DLHC | PRLD |
|---|---|---|
| Price | $6.23 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 7.8K | ★ 305.5K |
| Earning Date | 05-06-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,923,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $0.05 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.57 | ★ 73.43 |
| 52 Week Low | $2.72 | $0.61 |
| 52 Week High | $8.09 | $4.19 |
Technical Indicators
Market Signals| Indicator | DLHC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 54.67 |
| Support Level | $5.56 | $1.02 |
| Resistance Level | $6.88 | $4.10 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 100.00 | 41.78 |
Price Performance
Historical ComparisonAbout DLHC DLH Holdings Corp.
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.